Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery
Study Number: S1801
This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab before and after surgery may work better in treating melanoma.
Just in Time Trial
- Navigator Carrie, 309-243-3621 firstname.lastname@example.org
- Jessica, 309-243-3615, email@example.com
- Amanda , 309-243-3663, firstname.lastname@example.org